
PMN Stock Forecast & Price Target
PMN Analyst Ratings
Bulls say
ProMIS Neurosciences is a promising clinical-stage biotechnology company with a differentiated monoclonal antibody, PMN310, designed to selectively target toxic, misfolded amyloid-beta oligomers in early Alzheimer's disease (AD). If proven effective, the drug has the potential to overcome safety hurdles and directly compete with established players. The upcoming 12-month data in the PRECISE-AD Phase 1b study will provide a comprehensive assessment of the drug's safety, biomarker, and clinical outcomes, and any observed efficacy with low risks of ARIA would support its potential for uptake. The addition of predictive biomarkers and FDA engagement in the future highlights the company's commitment and potential for success in the AD market.
Bears say
ProMIS Neurosciences is a clinical-stage biotechnology company with a potential for growth, driven by its product candidate PMN310, which is currently in Phase Ib study for treatment of Alzheimer's disease. However, challenges regarding efficacy and potential safety issues could hinder the company's success, along with the need for financing. Additionally, there is competition in the market as well as risks associated with regulatory approval.
This aggregate rating is based on analysts' research of ProMIS Neurosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
PMN Analyst Forecast & Price Prediction
Start investing in PMN
Order type
Buy in
Order amount
Est. shares
0 shares